Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Apr 14;107(5):700–707. doi: 10.1111/cas.12917

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Immunostaining of CD44 CD163, and CD204 in clear cell renal cell carcinoma (ccRCC). (a) Cancer cells and macrophages are positive for CD44, and the distribution of CD44⁺ cancer cells is heterogeneous. CD163 and CD204 were used as macrophage markers. The results of two patients are shown. (b) Patients were divided into four groups according to the percentage of CD44⁺ cancer cells. (c) The numbers of CD163⁺ and CD204⁺ tumor‐associated macrophages (TAM) were counted in the CD44⁻ and CD44⁺ areas, respectively. A paired Student t‐test was performed. (d) The numbers of CD163⁺ and CD204⁺ TAM were counted in all cases, and the numbers of TAM were compared between CD44⁻ cases and CD44⁺ cases. A Mann–Whitney U‐test was performed.